Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application

Overview

The purpose of this study is to compare the ovicidal activity of three head lice treatment products. The study population will consist of Queensland primary school-aged children (Grades 1 – 7) who have at least 20 live eggs on the hair and who have not used any head lice product in the four weeks prior to the study. Enrollment will continue to achieve 30 subjects in each treatment group (total of 90 subjects).

Full Title of Study: “A Randomised, Assessor Blind, Parallel Group, Comparative Trial of the Ovicidal Activity of Three Head Lice Products (NeutraLice Lotion®, NeutraLice Advance® and Moov Head Lice Solution®) After a Single Application”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2009

Detailed Description

Subjects will be examined for the presence of head louse eggs. Those subjects who have at least 20 live eggs will be randomised into one of 3 treatment groups: NeutraLice Lotion, NeutraLice Advance or Moov Head Lice Solution treatment groups. Pre-treatment: 10 eggs will be removed from the head by cutting the single hair with the live egg attached, before the treatment. Treatment: The subject will then receive a single treatment application according to manufacturers instructions. Then the treatment will be washed from the hair as per the manufacturer's instructions. Post-treatment: At least 10 treated (live) eggs will be removed from the head by cutting the single hair with the egg attached, after the treatment. All of the eggs will be held in an incubator for 14 days. The proportion of eggs which hatch after 14 days will be compared for the pre-treatment and post-treatment eggs. Demographic data will be collected for each subject (hair type, hair colour, hair length, subject age, subject sex) to investigate the affect of hair type on ovicidal efficacy.

Interventions

  • Drug: NeutraLice Lotion
    • Head lice topical application to be applied once for 10 minutes.
  • Drug: NeutraLice Advance Solution
    • head lice application to be applied once for 10 minutes
  • Drug: Moov Head Lice Solution
    • Single application for head lice with 10 min application time.

Arms, Groups and Cohorts

  • Experimental: NeutraLice Lotion
    • Single application of head lice product.
  • Experimental: NeutraLice Advance
    • single application of head lice product
  • Active Comparator: Moov Head Lice Solution
    • Single application for head lice with 10 min application time.

Clinical Trial Outcome Measures

Primary Measures

  • Ovicidal efficacy index (OEI) The proportion of treated eggs hatched in-vitro divided by the proportion of pre-treated eggs hatched in-vitro expressed as a percentage up to and including 14 days after collection and incubation.
    • Time Frame: ovicidal activity assessed after 14 days

Participating in This Clinical Trial

Inclusion Criteria

  • Male or female primary school-aged children. – Presence of at least 20 live head lice eggs on the hair. The presence of live head lice eggs will be determined from a visual inspection of the hair. – Parent / Guardian have given written informed consent to their child's participation in the trial. Exclusion Criteria:

  • History of allergies or adverse reactions to head lice products or the components of the specific products being tested. – Treatment with any head lice product in the 4 weeks prior to participation in this trial. – Treatment with hair dyes and bleaches within 4 weeks prior to participation in this trial. – Presence of scalp disease(s).

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 12 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Altman Biomedical Consulting Pty. Ltd.
  • Provider of Information About this Clinical Study
    • Assoc. Prof. Stephen Barker, Parasitology Section, School of Chemistry & Molecular Biosciences, & UniQuest Pty Ltd
  • Overall Official(s)
    • Stephen Barker, PhD, Principal Investigator, University of Queensland, Queensland, Australia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.